Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

ram.

IND Filed with FDA to Enable Clinical Testing of New Oral Drug for Bone Disease

In August 2007, the Company filed an Investigational New Drug Exemption (IND) with the FDA's Division of Endocrinologic and Metabolic Drugs for a newly formulated compound, known as G4544. Developed out of a joint collaboration with Emisphere Technologies, Inc., G4544 is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite. This compound is a highly potent inhibitor of calcium release from bone. Diseases associated with accelerated bone loss include hypercalcemia, bone metastases, Paget's disease and osteoporosis. Genta currently intends to manage the clinical development process of oncology indications and to seek a development and commercial partner for non-malignant metabolic bone diseases. Assuming regulatory concurrence with the IND plan to establish bioequivalence with the FDA-approved parenteral product, Genta expects to initiate the initial clinical trial of G4544 in the second half of 2007.

Stock Trading and Capital Structure

In July, Genta was notified by NASDAQ that the Company has demonstrated compliance with all NASDAQ Marketplace rules. As a consequence, the NASDAQ Listings Qualifications Panel determined that Genta's common stock will continue to be listed on the NASDAQ Global Market. As part of the plan to establish compliance, Genta stockholders approved a one-for-six reverse split of the Company's shares of common stock, which reduced the number of outstanding shares to approximately 31 million. The Company's common stock temporarily trades under the symbol "GNTAD". On or about August 10, 2007, the Company expects that the common stock will resume trading under its former symbol, "GNTA".

Financial Information

All share and per share data included in this press release have been retroactively adjusted to account for the effect of the 1-for-6 reverse stock split on July 13, 2007. The Co
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... prospects for leading ophthalmic drug companies  What ... pharma ophthalmic industry ? Visiongain,s brand new report ... opportunities and prospects there. Our 242-page report ... lucrative areas in the industry and the future market ...
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... 2011 Aircraft Medical ("Aircraft"), the UK ... an exclusive agreement with Covidien (NYSE: COV ... 2010 revenue of $10.4 billion, and 41,000 employees worldwide. ... will market and distribute Aircraft,s proprietary McGRATH ® ...
... /PRNewswire-iReach/ -- Medical Inflatable Exhibits, Inc. today announced ... MEGA Lungs ™, joining the MEGA Heart™ and MEGA ... models of the human anatomy.  The MEGA Lungs are ... (Photo:   http://photos.prnewswire.com/prnh/20111012/CG83862 ) The MEGA ...
Cached Medicine Technology:Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2A Breath of Fresh Air for Lung Cancer Awareness Month 2A Breath of Fresh Air for Lung Cancer Awareness Month 3
(Date:3/30/2015)... Considered to be the best assessment tool for ... community, this next generation of the IT Audit ... data and frameworks with virtually endless possibilities. These new ... logic features are a technological force to be reckoned ... “The IT Audit Machine is just one of the ...
(Date:3/30/2015)... 2015 A new recruitment site has ... for their next career move. , Millions of new ... for those with skills in the booming data and ... is a jobs aggregator, pulling in opportunities from both ... them individually to help candidates find suitable big data ...
(Date:3/30/2015)... March 30, 2015 TherapySites, ... for mental health professionals, announced today its affiliation ... TherapySites to extend their online marketing solutions to ... , "As we continue to see advancements in ... the Internet effectively in order to succeed,” said ...
(Date:3/30/2015)... Developing new treatments for Diabetes Type 2 ... models that recapitulate only some subset of the specific ... , A company that specializes in developing and manufacturing ... has created iPSC-derived cardiomyocytes (heart muscle cells), which have ... vitro models of Diabetes Type 2. The development process ...
(Date:3/30/2015)... March 30, 2015 Bunion Bootie ... Buy them for family members, friends...and yourself and save. For ... can save an additional 10%, on top of discounts already ... code "EasterPR" at checkout. The more Bunion Booties purchased, the ... spacers, and bunion pads, Bunion Bootie can be worn comfortably ...
Breaking Medicine News(10 mins):Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:TherapySites (Websites for Therapists) Partners with BehaveNet 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2
... primates points to possible weapon against human infection with ... Researchers have successfully tested several Ebola vaccines in monkeys ... vaccine for one of the world,s deadliest diseases. ... overlooked. We are seeing more and more naturally occurring ...
... The Palace was the backdrop,for technology,s royalty last ... "Best in Show" at the 2008 NJ Venture Conference., ... Succeed" and,Switch2Health of New Brunswick took the prize for ... crowd of more than 500 entrepreneurs,and investors looking for ...
... and Chapel Hill, N.C. March 31, 2008 - ... Journal of Medicine, which concluded that lung transplants were ... the latest issue of Pediatric Transplantation refute the conclusions ... flawed. , According to two rebuttals published in the ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... on ... NEW YORK, March 31 For expectant parents, choosing ... significant decision. But,there are many things that go on behind ... properly in order to ensure a,positive patient experience and a ...
... Lowering the blood pressure of elderly patients could cut ... of cardiovascular events by a third, according to a ... American College of Cardiology in Chicago and published simultaneously ... 3,845 patient Hypertension in the Very Elderly Trial (HYVET), ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 3Health News:Lung transplants not dangerous for children with cystic fibrosis, after all 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3
LB Agar plates with 10mM Magnesium Sulfate....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... Molecular Biology Buffers are ready-to-use solutions ideal ... applications. Each reagent is prepared with 18 ... filter, and filled into sterile bottles., ... control standards to ensure lot-to-lot consistency. ...
Medicine Products: